Cure8 news brief
Patients and clinicians interested in Crohn’s treatments may see earlier access to a subcutaneous Skyrizi induction option in 2027, and broader payer coverage timing can affect when patients can actually start or switch to this therapy.
The article also flags pricing, reimbursement, and trial uncertainties that could influence drug availability and cost.
Patients with Crohn's disease, clinicians prescribing biologics/JAK inhibitors, people on Skyrizi or Rinvoq, patient advocates tracking drug access and reimbursement, and health-policy or payer stakeholders.
The article summarizes AbbVie’s financial results and management commentary.
It emphasizes strong sales growth for Skyrizi and Rinvoq, forecasts raised 2026 revenue and EPS guidance, and notes that broader payer access for subcutaneous Skyrizi induction for Crohn’s disease could start ramping in early 2027 but may take ~60 days or longer for full payer coverage.
The article also covers other AbbVie franchise areas (neuroscience, oncology) and pipeline/regulatory milestones that could affect future commercial performance.
The reporting is business-focused: it describes commercial expectations, regulatory submission timelines, and reimbursement considerations rather than providing clinical guidance or new trial efficacy results. If you are tracking treatment availability, coverage, or the company's pipeline, the timing and payer-access notes are the most relevant takeaways.
This is a financial/earnings report summarizing company commentary and guidance. It highlights expected commercial and regulatory timelines (including payer-access estimates) rather than presenting new clinical trial results. Payer coverage timing and reimbursement decisions can vary by region and insurer, which may delay real-world access beyond company estimates.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
An FDA approval of Skyrizi for subcutaneous induction could affect treatment options and access for people with Crohn’s disease. Corporate moves (acquisition, guidance) can influence drug availability, pricing, and...
Growth and new approvals for Skyrizi and Rinvoq may increase treatment options and influence which drugs gastroenterologists prescribe for Crohn’s disease and ulcerative colitis. Changes in approvals, dosing options, and...
This article explains why two widely used IBD drugs from AbbVie (Skyrizi and Rinvoq) are central to the company’s growth and describes ongoing development efforts that could expand treatment options and indications in...
